Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia
Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the submission of its Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for the vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (“VT”) in patients with ischemic or non-ischemic structural heart disease.
New Adagio Medical Publication Highlights Consistent Safety and Effectiveness with Ultralow Temperature Ablation in Broad Range of Patients with Ventricular Tachycardia
Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of results from the U.S. Early Feasibility Study (“EFS”) evaluating ultralow temperature cardiac ablation (“ULTC”) for the treatment of scar-related ventricular tachycardia (“VT”). The study was published in Circulation: Arrythmia and Electrophysiology.
Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors
Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company’s Audit Committee and Compensation Committee.
